Pathologic Factors Associated with Prognosis after Adjuvant Chemotherapy in Stage II/III Microsatellite-Unstable Colorectal Cancers
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: Although there are controversies regarding the benefit of fluoropyrimidine-based adjuvant chemotherapy in patients with microsatellite instability–high (MSI-H) colorectal cancer (CRC), the pathologic features affecting postchemotherapeutic prognosis in these patients have not been fully identified yet. Methods: A total of 26 histopathologic and immunohistochemical factors were comprehensively evaluated in 125 stage II or III MSI-H CRC patients who underwent curative resection followed by fluoropyrimidine-based adjuvant chemotherapy. We statistically analyzed the associations of these factors with disease-free survival (DFS). Results: Using a Kaplan-Meier analysis with log-rank test, we determined that ulceroinfiltrative gross type (p=.003), pT4 (p<.001), pN2 (p=.002), perineural invasion (p=.001), absence of peritumoral lymphoid reaction (p=.041), signet ring cell component (p=.006), and cribriform comedo component (p=.004) were significantly associated with worse DFS in patients receiving oxaliplatin-based adjuvant chemotherapy (n=45). By contrast, pT4 (p<.001) and tumor budding-positivity (p=.032) were significant predictors of poor survival in patients receiving non-oxaliplatin–based adjuvant chemotherapy (n=80). In Cox proportional hazards regression model-based univariate and multivariate analyses, pT category (pT1-3 vs pT4) was the only significant prognostic factor in patients receiving non-oxaliplatin–based adjuvant chemotherapy, whereas pT category, signet ring cell histology and cribriform comedo histology remained independent prognostic factors in patients receiving oxaliplatin-based adjuvant chemotherapy. Conclusions: pT4 status is the most significant pathologic determinant of poor outcome after fluoropyrimidine-based adjuvant chemotherapy in patients with stage II/III MSI-H CRC.
Abstract
Background: Although there are controversies regarding the benefit of fluoropyrimidine-based adjuvant chemotherapy in patients with microsatellite instability–high (MSI-H) colorectal cancer (CRC), the pathologic features affecting postchemotherapeutic prognosis in these patients have not been fully identified yet. Methods: A total of 26 histopathologic and immunohistochemical factors were comprehensively evaluated in 125 stage II or III MSI-H CRC patients who underwent curative resection followed by fluoropyrimidine-based adjuvant chemotherapy. We statistically analyzed the associations of these factors with disease-free survival (DFS). Results: Using a Kaplan-Meier analysis with log-rank test, we determined that ulceroinfiltrative gross type (p=.003), pT4 (p<.001), pN2 (p=.002), perineural invasion (p=.001), absence of peritumoral lymphoid reaction (p=.041), signet ring cell component (p=.006), and cribriform comedo component (p=.004) were significantly associated with worse DFS in patients receiving oxaliplatin-based adjuvant chemotherapy (n=45). By contrast, pT4 (p<.001) and tumor budding-positivity (p=.032) were significant predictors of poor survival in patients receiving non-oxaliplatin–based adjuvant chemotherapy (n=80). In Cox proportional hazards regression model-based univariate and multivariate analyses, pT category (pT1-3 vs pT4) was the only significant prognostic factor in patients receiving non-oxaliplatin–based adjuvant chemotherapy, whereas pT category, signet ring cell histology and cribriform comedo histology remained independent prognostic factors in patients receiving oxaliplatin-based adjuvant chemotherapy. Conclusions: pT4 status is the most significant pathologic determinant of poor outcome after fluoropyrimidine-based adjuvant chemotherapy in patients with stage II/III MSI-H CRC.
참고문헌 (28)
- Wolpin BM, "Systemic treatment of colorectal cancer", Gastroenterology, 134, pp.1296~1310 (2008)
- Kim JH, "Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer", World J Gastroenterol, 20, pp.4230~4243 (2014)
- Carethers JM, "Mismatch repair proficiency and in vitro response to 5-fluorouracil", Gastroenterology, 117, pp.123~131 (1999)
- Arnold CN, "Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines", Int J Cancer, 106, pp.66~73 (2003)
- Jenkins MA, "Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability : a population-based study", Gastroenterology, 133, pp.48~56 (2007)
- Ligtenberg MJ, "Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3’ exons of TACSTD1", Nat Genet, 41, pp.112~117 (2009)
- 김정호, "Differential Features of Microsatellite-Unstable Colorectal Carcinomas Depending on EPCAM Expression Status", Journal of Pathology and Translational Medicine, 48(4), pp.276~282 (2014), 대한병리학회[DOI]
- Kim JH, "Loss of CDX2", CK20expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer, 2013, pp.37, 1532~1541
- Ricciardiello L, "High thymidylate synthase expression in colorectal cancer with microsatellite instability : implications for chemotherapeutic strategies", Clin Cancer Res, 11, pp.4234~4240 (2005)
- Sinicrope FA, "Thymidylate synthase expression in colon carcinomas with microsatellite instability", Clin Cancer Res, 12, pp.2738~2744 (2006)
- Popat S, "Inter-relationship between microsatellite instability, thymidylate synthase expression, and p53 status in colorectal cancer: implications for chemoresistance", BMC Cancer, 6, pp.150~ (2006)
- Kim GP, "Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study", J Clin Oncol, 25, pp.767~772 (2007)
- Dorard C, "Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis", Nat Med, 17, pp.1283~1289 (2011)
- Kim JH, "Expression status of wild-type HSP110correlates with HSP110 T17 deletion size and patient prognosis in microsatellite-unstable colorectal cancer", Mod Pathol, 27, pp.443~453 (2014)
- Bosman FT, "WHO classification of tumours of the digestive system" (2010), IARC Press
- Ueno H, "Risk factors for an adverse outcome in early invasive colorectal carcinoma", Gastroenterology, 127, pp.385~394 (2004)
- Klintrup K, "Inflammation and prognosis in colorectal cancer", Eur J Cancer, 41, pp.2645~2654 (2005)
- Ueno H, "Objective criteria for crohn-like lymphoid reaction in colorectal cancer", Am J Clin Pathol, 139, pp.434~441 (2013)
- Wick MR, "Sporadic medullary carcinoma of the colon: a clinicopathologic comparison with nonhereditary poorly differentiated enteric-type adenocarcinoma and neuroendocrine colorectal carcinoma", Am J Clin Pathol, 123, pp.56~65 (2005)
- Bettington M, "The serrated pathway to colorectal carcinoma: current concepts and challenges", Histopathology, 62, pp.367~386 (2013)
- Chirieac LR, "Phenotype of microsatellite-stable colorectal carcinomas with CpG island methylation", Am J Surg Pathol, 29, pp.429~436 (2005)
- Johnston PG, "The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer", J Clin Oncol, 12, pp.2640~2647 (1994)
- Marzouk O, "Review of histopathological and molecular prognostic features in colorectal cancer", Cancers (Basel), 3, pp.2767~2810 (2011)
- Richards CH, "The relationships between cellular components of the peritumoural inflammatory response, clinicopathological characteristics and survival in patients with primary operable colorectal cancer", Br J Cancer, 106, pp.2010~2015 (2012)
- Tesniere A, "Immunogenic death of colon cancer cells treated with oxaliplatin", Oncogene, 29, pp.482~491 (2010)
- Ross JS, "Biomarker-based prediction of response to therapy for colorectal cancer : current perspective", Am J Clin Pathol, 134, pp.478~490 (2010)
- Li J, "TNM staging of colorectal cancer should be reconsidered by T stage weighting", World J Gastroenterol, 20, pp.5104~5112 (2014)
- Snaebjornsson P, "pT4 stage II and III colon cancers carry the worst prognosis in a nationwide survival analysis : Shepherd’s local peritoneal involvement revisited", Int J Cancer, 135, pp.467~478 (2014)